Expression of human endogenous retrovirus env genes in the blood of breast cancer patients

• Published in: International journal of molecular sciences Vol. 15; no. 6; pp. 9173 - 9183
• Main Authors: Rhyu, Dong-Won, Kang, Yun-Jeong, Ock, Mee-Sun, Eo, Jung-Woo, Choi, Yung-Hyun, Kim, Wun-Jae, Leem, Sun-Hee, Yi, Joo-Mi, Kim, Heui-Soo, Cha, Hee-Jae
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.05.2014; MDPI
• Subjects: Adult; Aged; Antineoplastic Agents, Phytogenic - therapeutic use; blood; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - radiotherapy; Breast Neoplasms - virology; Communication; Endogenous Retroviruses - genetics; Endogenous Retroviruses - metabolism; env; Female; Gene Expression; Gene Products, env - blood; Gene Products, env - genetics; Gene Products, env - metabolism; HERV; Human endogenous retrovirus; Humans; Middle Aged; mRNA; Paclitaxel - therapeutic use; Plasma; Polymerase chain reaction; Proteins; Real-Time Polymerase Chain Reaction; realtime PCR; RNA, Messenger - metabolism
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms15069173

Human endogenous retroviruses (HERV) env proteins have been recently reported to be significantly up-regulated in certain cancers. Specifically, mRNA and protein levels of HERV-K (HML-2) are up-regulated in the blood plasma or serum of breast cancer patients. Here, we collected blood samples of 49 breast cancer patients and analyzed mRNA expressions of various HERVs env genes including HERV-R, HERV-H, HERV-K, and HERV-P by real-time PCR. The expression of env genes were significantly increased in the blood of primary breast cancer patients but were decreased in patients undergoing chemotherapy to a similar level with benign patients. When we compared the group currently undergoing chemotherapy and those patients undergoing chemotherapy simultaneously with radiotherapy, HERVs env genes were reduced more in the chemotherapy only group, suggesting that chemotherapy is more effective in reducing HERV env gene expression than is radiotherapy. Among chemotherapy groups, HERV env gene expression was the lowest in the taxotere- or taxol-treated group, suggesting that taxotere and taxol can reduce HERVs env expression. These data suggest the potential to use HERVs env genes as a diagnosis marker for primary breast cancer, and further studies are needed to identify the mechanism and physiological significance of the reduction of HERV env gene expression during chemotherapy.